PellePharm Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

PellePharm General Information

Description

Developer of skin cancer therapeutics intended to mitigate the tumor burden of basal cell carcinomas. The company's therapeutics include a topical hedgehog inhibitor, which decreases the number of surgically-eligible basal cell carcinomas in Gorlin syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3160 Porter Drive
  • Suite 250
  • Palo Alto, CA 94304
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3160 Porter Drive
  • Suite 250
  • Palo Alto, CA 94304
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PellePharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Apr-2023 Completed Generating Revenue
6. Later Stage VC 20-Nov-2018 Completed Generating Revenue
5. Later Stage VC (Series C) 18-Jun-2018 Completed Generating Revenue
4. Debt - General 29-Mar-2018 Completed Generating Revenue
3. Later Stage VC (Series B2) 31-Jul-2017 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M Completed Generating Revenue
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M Completed Generating Revenue
To view PellePharm’s complete valuation and funding history, request access »

PellePharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B2
Series B 3,888,889 $0.000100 $0.09 $1.17 $1.17 1x $1.17 8.67%
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 8.27%
To view PellePharm’s complete cap table history, request access »

PellePharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of skin cancer therapeutics intended to mitigate the tumor burden of basal cell carcinomas. The company's ther
Drug Discovery
Palo Alto, CA
8 As of 2021

Branford, CT
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PellePharm Competitors (28)

One of PellePharm’s 28 competitors is Azitra, a Formerly VC-backed company based in Branford, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Azitra Formerly VC-backed Branford, CT
Xalud Therapeutics Venture Capital-Backed New York, NY
Vera Therapeutics Formerly VC-backed Brisbane, CA
Bolden Therapeutics Venture Capital-Backed Providence, RI
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
You’re viewing 5 of 28 competitors. Get the full list »

PellePharm Patents

PellePharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2017139497-A1 Hedgehog inhibitor for use in relief of and treatment of pruritus or itching Inactive 11-Feb-2016
US-20170231968-A1 Method for relief of and treatment of pruritus Inactive 11-Feb-2016
JP-6796638-B2 Topical formulations and their use for the delivery of hedgehog inhibitory compounds Active 04-Jun-2015
WO-2016196928-A1 Topical formulations for delivery of hedgehog inhibitor compounds and use thereof Inactive 04-Jun-2015
JP-2021014469-A Topical formulations for delivery of hedgehog inhibitor compounds and uses thereof Pending 04-Jun-2015 A61K31/496
To view PellePharm’s complete patent history, request access »

PellePharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PellePharm Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
LEO Pharma PE-Backed Company Minority
EcoR1 Capital Venture Capital Minority
Angel (individual) Minority
BridgeBio Pharma Corporation Minority
Piedmont Trust Company Limited Partner Minority
You’re viewing 5 of 6 investors. Get the full list »

PellePharm Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
PellePharm (Hedgehog Signaling Pathway Blocker in San Francisco) San Francisco, CA

PellePharm FAQs

  • When was PellePharm founded?

    PellePharm was founded in 2012.

  • Where is PellePharm headquartered?

    PellePharm is headquartered in Palo Alto, CA.

  • What is the size of PellePharm?

    PellePharm has 8 total employees.

  • What industry is PellePharm in?

    PellePharm’s primary industry is Drug Discovery.

  • Is PellePharm a private or public company?

    PellePharm is a Private company.

  • What is PellePharm’s current revenue?

    The current revenue for PellePharm is .

  • How much funding has PellePharm raised over time?

    PellePharm has raised $113M.

  • Who are PellePharm’s investors?

    LEO Pharma, EcoR1 Capital, , BridgeBio Pharma, and Piedmont Trust Company are 5 of 6 investors who have invested in PellePharm.

  • Who are PellePharm’s competitors?

    Azitra, Xalud Therapeutics, Vera Therapeutics, Bolden Therapeutics, and Vertex Pharmaceuticals are some of the 28 competitors of PellePharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process